Adequate levels of thyroid hormone (TH) are needed for proper brain development, deficiencies may lead to adverse neurologic outcomes in humans and animal models. Environmental chemicals have been linked to TH disruption, yet the relationship between developmental exposures and decline in serum TH resulting in neurodevelopmental impairment is poorly understood. The present study developed a quantitative adverse outcome pathway where serum thyroxin (T4) reduction following inhibition of thyroperoxidase in the thyroid gland are described and related to deficits in fetal brain TH and the development of a brain malformation, cortical heterotopia. Pregnant rats were exposed to 6-propylthiouracil (PTU 0, 0.1, 0.5, 1, 2, or 3 parts per million [ppm]) from gestational days 6-20, sequentially increasing PTU concentrations in maternal thyroid gland and serum as well as in fetal serum. Dams exposed to 0.5 ppm PTU and higher exhibited dosedependent decreases in thyroidal T4. Serum T4 levels in the dam were significantly decreased with exposure to 2 and 3 ppm PTU. In the fetus, T4 decrements were first observed at a lower dose of 0.5 ppm PTU. Based on these data, fetal brain T4 levels were estimated from published literature sources, and quantitatively linked to increases in the size of the heterotopia present in the brains of offspring. These data show the potential of in vivo assessments and computational descriptions of biologic responses to predict the development of this structural brain malformation and use of quantitative adverse outcome pathway approach to evaluate brain deficits that may result from exposure to other TH disruptors.
An "adverse outcome pathway" (AOP) is a conceptual construct that portrays existing knowledge concerning the biologically plausible linkages between a direct molecular target of a xenobiotic and an adverse outcome (AO) that occurs at a level of biologic organization amenable to risk assessment (Villeneuve et al., 2014) . Computational predictive modeling can be applied to quantitatively describe the sequences of key events (KEs) and their relationships (KE relationships, KER) and the biologic processes of pathogenesis that comprise an AOP. The reliability of predictions from these models is improved with greater understanding of the biologic foundation of the AOP (Edwards et al., 2016) . Predictions also are improved by complete appreciation of the quantitative determinants from upstream biologic perturbations to subsequent downstream overt organismal effects comprising the AO (Edwards et al., 2016; Parham et al., 2012; Wise et al., 2012) . When mathematical descriptions of these relationships are biologically driven equations, a mechanistic quantitative AOP (qAOP) is derived. More commonly, full biologic understanding and data to support quantification are not available, so empirically derived mathematical functions are used to provide estimates of these missing parameters. In the present study, an empirical qAOP was constructed to describe the neurologic effects induced by a classic thyroid hormone (TH) synthesis inhibitor on the developing fetal brain.
Adequate supplies of THs, namely thyroxine (T4) and triiodothyronine (T3), are crucial for normal brain development (Bernal, 2015; Howdeshell, 2002; Miller et al., 2009; Morreale de Escobar et al., 2004; Williams, 2008; Zoeller and Crofton, 2005) . Even mild decreases in maternal TH levels during development have been implicated in poor neurologic outcomes in children, including lower IQ, cognitive impairments, and learning disabilities (Ghassabian et al., 2014; Haddow et al., 1999; Korevaar et al., 2016; Rovet, 2014) . In early gestation, TH reaches the developing fetal brain by placental transfer from the mother to the fetal circulation . The fetal thyroid gland begins to function during the second half of pregnancy, the mother being the sole source of TH up to that point. In rodents, the fetal gland is nonfunctional until late gestation (gestational day [GD] 17 with birth occurring on GD 22) (Bernal, 2015; Morreale de Escobar et al., 2004; Obregon et al., 2007) . Just before birth, approximately 17% of fetal T4 derives from the dam despite the presence of a functioning thyroid gland . In humans, these estimates range 30%-50% (Morreale de Escobar et al., 2004; Obregon et al., 2007; Vulsma et al., 1989) .
A number of pharmaceutical and environmental chemicals reduce circulating levels of TH by inhibiting the synthesis enzyme, thyroperoxidase (TPO) (Brucker-Davis, 1998) . As depicted in Figure 1 , TPO has 2 main functions in the synthesis of TH in both rats and humans: (1) it catalyzes the iodination of tyrosine on the thyroglobulin protein in the thyrocyte to produce monoand di-iodotyrosines (MIT and DIT, respectively); and (2) it couples MIT and DIT, to form tri-(T3, 1 MIT and 1 DIT molecule) and tetra-(T4, 2 DIT molecules) iodothyronines for release into the circulation (Nagasaka and Hidaka, 1976; Ohmori et al., 1989; Taurog, 1976) . PTU is used in the treatment of hyperthyroidism, reducing TH synthesis in the thyroid gland and decreasing circulating concentrations of T3 and T4 (Cooper et al., 1983) . In addition to being a potent TPO inhibitor, PTU also inhibits deiodinase 1 (Doi1) in humans and rodents, the enzyme responsible for converting T4 to its active form T3 in a number of tissues, most notably the liver (Cooper et al., 1983; Geffner et al., 1975; Visser et al., 1983) . The main deiodinase in brain responsible for this conversion is Dio2 and it not affected by PTU.
PTU has been used extensively as a research tool to study the thyroid system in general (Cooper et al., 1983; Hood et al., 1999) and its interplay with the development of many organ systems, most notably the brain (Axelstad et al., 2008; Gilbert, 2011; Obregon et al., 2005) . Although the common use of PTU in research settings has resulted in a rich database documenting the effects of TH insufficiency on various organ systems, quantitative dose-response relationships between applied dose and TH-dependent regulation of brain development have not been adequately described. This stems from the primary use of single high-dose studies and the lack of clear robust markers of THdependent neurotoxicity that are evident at moderate degrees of TH reduction. These factors have severely limited the application of quantitative analyses to the study of TH insufficiencies and neurodevelopment impairment.
Our laboratory has worked to address this data gap. We have recently reported a structural malformation in the brains of rats born to hypothyroid dams that lends itself to the development of a qAOP. Rat dams administered a range of PTU doses in drinking water throughout gestation and lactation give birth to offspring exhibiting an abnormal cluster of neurons, named a cortical heterotopia, within the normally neuron sparse white matter of the corpus callosum (Gilbert et al., 2014; Goodman and Gilbert, 2007) . We have shown that the development of a heterotopia requires prenatal TH insufficiency, and this malformation appears early in neonatal development. The malformation persists and can be observed in the adult brain. Heterotopias can be reversed with TH supplementation, and demonstrate a clear dose-dependency in response to graded and moderate levels of PTU exposure (Gilbert et al., 2014; Goodman and Gilbert, 2007) . We have selected the presence of a cortical heterotopia as a marker of TH-dependent developmental neurotoxicity to serve as the downstream apical event, the "AO" for an AOP linking TPO inhibition to developmental neurotoxicity (Figure 1 ).
Quantitative information on essential upstream events of this AOP is also lacking and required the development of sensitive analytical tools to measure PTU and TH concentrations in the serum and gland of the dam and serum of the fetus during the period of heterotopia formation. Herein we report results of these studies and their incorporation into an empirically-derived quantitative model that spans the cascade of events from TPO inhibition (MIE) leading to decreased TH synthesis in the pregnant dam and her progeny, through KEs in serum and brain hormone concentrations, to developmental neurotoxicity (AO) in a rodent model (Figure 1 ).
MATERIALS AND METHODS
Chemicals 6-Propyl-2-thiouracil enzyme inhibitor (6-propyl-2-sulfanylidene-1H-pyrimidin-4-one; PTU; CAS No. 51-52-5; purity >98%) for animal dosing and analytical grade PTU (purity 99.9%) used for liquid chromatography/tandem mass spectrometry (LC/MS/ MS) application, 3-iodo-L-thyrosine (MIT; (2S)-2-amino-3-(4-hydroxy-3-iodophenyl) propanoic acid; CAS No. 70-78-0; 96.8%), 3,5-diiodo-L-tyrosine dehydrate (DIT; 
Animal Treatment
The animal experiments were performed in accordance with the National Institutes of Health (NIH) Guide for Care and Use of Laboratory Animals. Timed pregnant Long-Evans rats were obtained from Charles River (Raleigh, North Carolina). The rats were shipped to the animal housing facility at the U.S. EPA at GD 2 and housed individually in standard hanging plastic cages. The animals were maintained on 12:12 h light/dark cycle and food (Purina 5008 rat chow) and deionized water, were provided ad libitum. Rats were randomly assigned to 1 of the 5 treatment groups. Control animals were exposed to drinking water alone. Treated animals were exposed to PTU at 0.1, 0.5, 1, 2, and 3 parts per million (ppm) PTU in drinking water from GD 6 through GD 20 (n ¼ 6-8/dose group). Dam weights were monitored throughout pregnancy. Dams were sacrificed by decapitation on GD 20 and trunk blood was collected. Trunk blood was also collected from all fetuses and pooled per litter, allowed to clot on ice, centrifuged at 25 000 rpm at 4 C for 30 min and serum stored at À80 C until analysis. A second set of dams was similarly exposed to 0 or 3 ppm PTU (n ¼ 8/dose group) from GD 6 and blood collected from the tail on GD 10, 15, and 20 to provide a more comprehensive estimation of serum TH over the course of pregnancy required for the modeling effort. Tail blood was collected by briefly restraining animals in a Tailveiner restrainer (Braintree Scientific Inc., Braintree, Massachusetts) with their tails exposed and swabbed with a warm towel. A 21-gauge heparinized butterfly needle was inserted into the tail vein and approximately 1 ml of blood was collected into a serum microtainer tube. Blood was centrifuged as described above and serum was separated and stored at À80 C for further analysis.
PTU Measurement in Serum and Thyroid Gland
Sample preparation. PTU levels were measured in GD20 dam thyroid gland and serum as well as in fetal serum by LC/MS/MS. PTU was extracted from serum and from thyroid gland by using a liquid-liquid extraction method. Thyroid glands were weighed and homogenized in 500 ml of Tris buffer saline. A 50-ml aliquot of thyroid gland homogenate or serum was transferred separately into a 2.0-ml polypropylene centrifuge tube followed by 10 ml of 6-propyl-2-thiouracil-d5 (PTU-d5) as the IS. Then 250 ml dithiothreitol (1% in phosphate buffered saline) was added to each sample and the tubes were vortex-mixed for 10 s. After mixing, the samples were placed in a 65 C water bath for 30 minutes to denature the proteins. After protein denaturation, samples were allowed to equilibrate to room temperature and 1-ml of ethyl acetate was added. PTU was extracted into the organic layer by pulse vortex-mixing for 10 min followed by centrifugation at 2000 Âg for 5 min. The upper organic layer was transferred to a high recovery autosampling vial and evaporated under N 2 at 50 C. The extracts were reconstituted in 50 ml of methanol/water (5:95, v/v) with 0.1% formic acid, vortex-mixed and analyzed by LC/MS/MS.
PTU quantification. The LC/MS/MS system consisted of a ThermoScientific Surveyor LC system and TSQ Quantum Ultra AM Mass Spectrometer. Chromatographic separation was performed on a Phenomenex Kinetex EVO-C18 column (2.6 mm, 100 mm Â 2.1 mm) at an oven temperature of 50 C. A linear gradient using 0.1% of formic acid in water as mobile phase A and 0.1% formic acid in methanol as mobile phase B were used at a flow rate of 0.3 m/min. The starting mobile phase composition was 95% in Phase A and 5% in Phase B. After 2 min the gradient PTU acts at these 2 sites to inhibit TH synthesis. The inset also depicts 3 other target MIE sites which are not described in this paper, one of which is a second site of PTU action. These include the sodium iodine symporter (NIS), and 2 metabolizing enzymes, iodotyrosine deiodinase 1 (DI) and iodothyrodine deiodinase (IYD) that contribute to iodine recycling. In addition to its effects on TPO, PTU also inhibits D1, blocking the removal of an iodide from T4 to form T3.
was ramped to 100% mobile phase B within 5 min and held at 100% mobile phase B for an additional 2 min. The column was re-equilibrated to starting conditions for 5 min. Analytes were detected by positive-ion heated electrospray ionization (ESI). Quantification and confirmation of PTU and PTU-d5 were achieved by selected reaction monitoring of the 2 most abundant ions generated from the collision-induced fragmentation of PTU. Deuterated labeled PTU (PTU-d5) was used as the IS for quantitation of PTU. The ratio of the quantifier ion to the confirmation ion was used to confirm the presence of PTU in the samples. Also, the presence was confirmed by relative retention time ratio of PTU to PTU-d5 in the calibration curve to the retention time ratios in the samples.
Quality control. Matrix-matched calibration standards were used for quantitation of the PTU levels in serum and in the thyroid glands. Calibration standards were prepared and analyzed in the same manner as project samples. The calibration curve used a minimum of 5 points over a range of 1-1000 ng/ml. The coefficient of determination for the calibration curve was !0.995. Each sample batch consisted of a method blank, PTU-spiked matrix-matched laboratory control sample, and a continuing calibration verification sample. Quality control parameters were experimentally determined by a method validation study. The study consisted of a recovery, method detection limit, matrix effect, and inter-and intra-day precision study. The calculated concentrations for PTU in the laboratory control sample and continuing calibration verification sample were within 80%-132% of actual spike amount as determined by the method validation study.
Thyroid Hormone Measurements in Serum and Thyroid Gland
Sample preparation. GD 20 dam serum T3 and T4, fetal serum T3 and T4, and MIT, DIT, T3, T4, and rT3 were measured in the thyroid gland of GD 20 dams using methods described in Hornung et al. (2015) . In this study, 20 ml of dam serum and 50 ml of fetal serum were placed into 1.5-ml polypropylene centrifuge tubes and spiked with 5 ml of a stable isotope solution ( 13 C 6 -T3 and 13 C 6 -T4 at 100 ng/ml in methanol). For the dam samples the following were added: 20 ml 1 N HCl, 100 ml H 2 O and 60 ml of 50% H 2 O:50% acetonitrile (v/v) with 0.1% formic acid. For the fetal samples the following were added: 50 ml 1 N HCl, 250 ml H 2 O and 150 ml of 50% H 2 O:50% acetonitrile (v/v) with 0.1% formic acid. The samples were vortexed and placed in an incubator at 37 C for 2 h. The samples were cooled to ambient temperature, diluted with an aqueous solution of 0.1% acetic acid (300 ml for dam and 750 ml for fetal samples) and vortexed. The hydrolyzed samples were processed through solid phase extraction (SPE) cartridges (Evolute CX, 1-ml cartridges, Biotage, Charlotte, North Carolina) using a vacuum manifold. Larger capacity SPE columns (ie, 1-ml, 25 mg) were used to process the fetal serum while 10 mg SPE columns were used for the dam serum. Prior to sample application, the SPE columns were conditioned with methanol followed by an aqueous solution of 0.1% acetic acid. The SPE columns were washed with an aqueous solution of 0.1% acetic acid followed by methanol. Thyroid hormones were eluted from the SPE sorbent using 2.5% NH 4 OH in methanol.
The SPE extracts were collected in 15-ml polypropylene centrifuge tubes and were evaporated to dryness with N 2 , in a heated water bath set at 42 C. The SPE dried extracts were reconstituted with 100 ml of 25% acetronitrile:75% H 2 O (v/v) with 0.1% formic acid. The reconstituted extracts were transferred to amber micro-sampling vials (Agilent Technologies, Santa Clara, California).
Glands were homogenized at the US EPA's Analytical Chemistry Research Core (RTP, North Carolina) and frozen aliquots were shipped to the US EPA's Mid-Continent Ecology Division (Duluth, Minnesota) where they were stored at À80 C.
For analysis, gland homogenates were thawed on ice, vortex mixed, and diluted by placing 5 ml of the homogenate into 1.5 ml polypropylene centrifuge tubes containing 495 ml protein digest buffer (PDB):100 mM Tris-Cl, pH 8.4, 2.5 mM 6-PTU, 1% Triton X-100. Aliquots (300 ml) of the diluted homogenate were placed into 1.5 ml polypropylene centrifuge tubes and an equal volume of 20 mg/ml pronase (>3.5 units/mg solid, Sigma P8811) prepared in PDB was added and the samples were vortex mixed. The samples were then incubated at 37 C with occasional vortex mixing. Subsamples (200 ml) were collected at 2 and 24 h digestion time points and placed into 0.5 ml polypropylene centrifuge tubes containing 200 ml of an aqueous solution of 4% formic acid and 20% acetonitrile to arrest the enzymatic digestion and adjust the sample pH. The samples were spiked with 5 ml of a stable isotope solution ( 13 C 6 -T2,
13
C 6 -T3, 13 C 6 -T4 at 100 ng/ml in methanol) (Isosciences) and vortex mixed.
Gland digests were then processed through SPE using a 96 well plate (Evolute Express CX, 10 mg, 1 ml, Biotage) and a positive pressure manifold (PPM-96, Biotage). Prior to sample application, the SPE wells were conditioned with methanol (400 ml) followed by 2% formic acid in water (2Â400 ml). The digested gland samples were transferred to the SPE wells and low pressure was applied. The SPE wells were washed with 50 mM ammonium acetate, pH 6 (400 ml) followed 2% formic acid in water (400 ml) and then methanol (400 ml). A 96-well collection plate was placed below the SPE plate and the analytes were eluted with a solution of 5% NH 4 OH in methanol (3Â200 ml). The SPE extracts were evaporated to dryness with heat and nitrogen gas using a 96 well plate SPE drying unit (SPE Dry 96, Biotage). The dried SPE extracts were reconstituted with 100 ml of 5% acetonitrile:95% H 2 O (v/v) with 0.1% formic acid. The reconstituted extracts were transferred to amber micro-sampling vials (Agilent Technologies).
Thyroid hormone quantification. The SPE reconstituted extracts from serum and thyroid gland were analyzed for TH by LC/MS/ MS (Hornung et al., 2015) . The LC/MS/MS system consisted of an Agilent 1290 ultra-high pressure LC with a 6490 triple quadrupole mass spectrometer. Chromatographic separation was performed by injecting 20 ml of sample into an Agilent Zorbax SB-C 18 RRHT column (1.8 mm, 50 mmÂ2.1 mm) which was maintained at 30 C. Thyroid hormones were eluted under gradient conditions (Hornung et al., 2015 ) with 5% acetonitrile:95% H 2 O (v/v) with 0.1% formic acid (mobile phase A) and 90% acetonitrile:10% H 2 O (v/v) with 0.1% formic acid (mobile phase B) at a flow rate of 0.4 ml/min. The LC column effluent was introduced into the mass spectrometer equipped with an ESI source and heated jet spray interface. The ESI source was operated in positive ion mode with multiple reaction monitoring (MRM). ESI source parameters, collision energies and MRM precursor to product ion transitions have been reported previously (Hornung et al., 2015) . Instrument control and data processing were performed using Agilent MassHunter software, version B.06.00. Analyte concentrations were determined using the IS method of quantification with stable isotopes 13 C 6 -T3 and 13 C 6 -T4 as IS for T3 and T4, respectively. For the thyroid gland, stable isotope 13 C 6 -T2 was used as the IS for MIT and DIT, 13 C 6 -T3 was the IS for T3 and rT3 and 13 C 6 -T4 was the IS for T4.
Quality control. Due to the anticipated wide range of endogenous TH concentrations in fetal and dam serum obtained from animals administered a range of PTU doses, 10-point calibration curves were run over a T3 and T4 range of 0.01-10 ng/ml. Calibration curves for T3 and T4 were linear with correlation coefficients !0.996. Stable isotopes 13 C 6 -T3 and 13 C 6 -T4, spiked into each sample at sample processing initiation, were used to correct TH concentrations in each sample for procedural recovery and MS ion suppression. Procedural blanks run with each sample set were below the lower limit of quantification (LLOQ). Serum method LLOQs for T3 and T4 were 0.05 ng/ml (20 ml dam serum) and 0.02 ng/ml (50 ml fetal serum). The serum method detection limit was 0.01 ng/ml (50 ml of serum). All the serum samples evaluated for T4 had levels above the LLOQ, but the highest PTU dose had T3 levels in fetal serum that were below the LLOQ of 0.02 ng/ml.
Eleven-point calibration curves with ranges of 0.01-20 ng/ml were used to account for the wide range of endogenous iodotyrosines and iodothyronines expected in the thyroid gland of PTU-treated animals. Calibration curves for MIT, DIT, T3 and T4 were linear with correlation coefficients !0.998. The calibration curve for rT3 was linear and had a correlation coefficient of 0.99. Stable isotopes, spiked into each sample, were used to correct analyte concentrations for method recoveries and MS ion suppression. Duplicate samples (n ¼ 9) were run to assess relative percent difference (precision). Mean precision of duplicate samples was 11.9% (MIT), 7.3% (DIT), 6.6% (T3), 8.4% (rT3) and 6.4% (T4). Procedural blanks, run with each sample set, were below the LLOQ. Gland method LLOQs were 0.25 ng/mg gland tissue.
Statistical Analysis
Dam and fetal PTU and TH serum and thyroid gland analyte concentrations were evaluated using general linear model analysis of variance (ANOVA) conducted using SAS version 9.2 (Cary, North Carolina). Group differences were determine using Dunnett's post hoc multiple comparisons tests with p < .05 considered statistically significant.
Conceptual Model and Quantitative Analysis
Conceptual model. The series of animal studies described above were designed to provide sufficient data on the main KEs of this qAOP in the pregnant dam and her fetus for the derivation of quantitative relationships (KERs). The overall conceptual structure of the computational approach for the AOP events in the dam and the fetus is depicted in Figure 2 , incorporating exposure to PTU and dosimetry of PTU in the serum and the gland.
Quantitative analysis. The quantitative relationships of modifying dosimetry factors (DF) are superimposed on the conceptual model structure of Figure 2 . When measured directly in the bounds of this study they are depicted as solid boxes coupled with solid brackets and arrows linking the 2 measures. Indirect estimates or those simulated based on values derived from the literature and not directly assessed in this study are shown in dashed boxes, brackets, and arrows. The conceptual model has 2 compartments, 1 for the dam where an estimate of the MIE was possible, and 1 for the fetus in which the AO is induced. The general flow of the model development is as follows: Parallel events exist in the maternal and the fetal compartments for Exposure/Dosimetry (DF) and for the MIE, KE1 and KE2 of the AOP. More direct assessments were possible for these measures in the dam than in the fetus. Serum PTU (DF1, DF4) and serum TH (KE2 dam , KE2 fetus ) were ascertained in both dam and fetus. Dam serum (DF1) and thyroid gland (DF2) PTU concentrations were coupled with T4 in the thyroid gland of the dam (DF3) to derive an estimate of TPO inhibition, the MIE of the AOP. Downstream from the MIE, the relationship between T4 concentrations in the thyroid gland and that in the serum (KE2 dam ) comprise KER1. PTU is transferred from the dam to the fetus (DF4). Although no measures of fetal thyroid gland function were possible, the indirect relationship between fetal serum PTU and fetal serum T4 (DF5) reflects the impact of TPO inhibition on the fetal thyroid function. Fetal serum hormone (KE2 fetus ) were coupled with literature estimates of fetal brain hormone (KE3) as described below and then further linked to the volume of the heterotopia, the AO. Table 4. MATLAB (version R2014b; The MathWorks, Inc. Natick, Massachusetts) M-files and functions were used to develop mathematical equations to characterize relationships between levels of PTU in the gland (DF3) and TH in the gland of the dam to simulate PTU-induced TPO inhibition (MIE). Microsoft Excel was used to determine the empirical relationship between T4 concentrations in the maternal gland and maternal (KER1) and fetal serum (KER2). Microsoft Excel was also used to determine correlations between serum PTU and T4 levels in fetus serum (DF4). MATLAB was again used to develop quantitative relationships between fetal T4 in serum and T4 in the fetal brain (KER3), and fetal brain T4 and the AO, heterotopia volume (KER4). Experimental and literature data describing temporal and doseresponse relationships were used to optimize the form and parameters used in the mathematical descriptions modeled using MATLAB functions. Finally, indirect KERs were described for fetal serum T4 and AO (KER5) and maternal serum T4 and AO (KER6) using regression.
All maternal and fetal measures for the main experiment were available for GD20. In a separate experiment, however, a series of serum samples was collected by tail vein puncture in dams from 0 and 3 ppm doses on GD10, GD15, and GD20. This enabled the development of functions describing dose-response and temporal changes over gestational time for the dam. Area under the curve (AUC) is often used to a provide full concentration-time profile of chemical exposure in vivo (Turner, 2013) . Therefore, we derived temporal AUC relationships for fetal serum T4 concentrations. We coupled these with fetal brain concentrations reported in the literature (Figure 1 of Ruiz de Ona et al., 1988) to derive empirical estimates of fetal brain T4 at varying levels of TPO inhibition. Finally, the generated AUCs for fetal brain T4 deficit were plotted against the volume of heterotopia (KER4 of Figure 2 ) reported by Gilbert et al. (2014) .
RESULTS

PTU and Hormones in Dam Thyroid Gland
Mean PTU concentrations in the thyroid gland of the dam were dramatically increased at all doses following 14-day exposure to PTU. At the lowest dose of 0.1 ppm PTU, mean concentrations of TH analytes, DIT, T4, T3, and rT3 were significantly increased, whereas MIT did not differ from control (Table 1) . Exposure to 0.5 ppm PTU decreased all thyroid gland analytes in a dosedependent manner. Significant reductions were seen in both DIT and T4 at 0.5 ppm and higher. All thyroid gland samples assayed for PTU, except controls, were above limit of quantitation (LLOQ) of 7 ng/ml and all the TH analytes were above LLOQ of 0.25 ng/mg.
PTU and THs in Dam Serum
With the exception of the 0 ppm dose group where PTU was not detected, all remaining dam serum samples assayed were above the LLOQ of 0.3 ng/ml. Maternal exposure to 0.5, 1, 2, and 3 ppm PTU in drinking water beginning on GD6 increased serum PTU in the dam by 85-, 113-, 258-, and 369-fold over control when assessed on GD20 ( Figure 3A ; F[5,36] ¼ 197.97, p < .0001). The lowest dose level of 0.1 ppm did not differ from control. A complimentary dose-dependent decrease in serum T4 accompanied the PTU serum profile with significant declines restricted to the 2 and 3 ppm dose levels ( Figure 3B, F Figure 3C ; equation 1). The slight increment in TH seen in the gland analysis at the lowest dose of PTU (0.1 ppm, Table 1 ) was mirrored in the pattern of serum T4 in the dam. In contrast to the gland TH concentrations as this low dose, the slight "bump" up in serum T4 failed to reach statistically significant levels ( Figure 3B ). Serum T3 concentrations in dams did not change at any dose level ( Figure 3D ). The slight increase in serum T4 is similar to those previously reported in adult male rats following exposure to low doses of PTU (1 ppm, lowest dose tested) and MMI (3 ppm) for periods of 7-14 days (Cooper et al., 1983; Hood et al., 1999) . It is unlikely that this reflects a compensatory change from feedback regulation by TSH as in both of these instances, slight increases in serum T4 were evident in the absence of an increase in TSH or a change in serum T3. As reviewed by Hood et al. (1999) , mechanisms activated to maintain serum T3 in the absence of increments in TSH may be responsible if this slight increment in serum T4. These include enhanced extrathyroidal deiodinase activity and increased hormone recovery from sulfatase activation and enterohepatic circulation. Data from the current study suggest an additional TSH-independent mechanism of intrathyroidal compensation whereby gland T3 and T4 concentrations are increased with the very modest challenges to TPO enzyme activation imbued by this very low dose of PTU (0.1 ppm). While confirmation of the independence of the serum T4 increases from TSH regulatory feedback mechanisms must await assessment of TSH at these low doses of PTU in the pregnant animal, this conjecture is supported by lack of effect on serum TSH in the lactating dams at low doses of PTU (Gilbert, 2011; Gilbert and Sui, 2006) .
Empirical Modeling of the MIE in the Maternal Thyroid Gland and Serum As depicted in Figure 1 , inhibition of TPO impairs TH synthesis in the thyroid gland. In the present study, TPO inhibition is clearly reflected in the precipitous drop in these gland analytes with increasing concentration of PTU (Table 1) . As in serum, T4 in the thyroid gland decreased as concentration of PTU in the thyroid gland rose. Based on these data, a one-compartment model for TPO inhibition by PTU in the dam thyroid gland at GD20 was developed to describe the MIE (DF3 and MIE of Figure 2 ). Gland T4 was selected as the synthesis product because it is most proximal to that released to serum and at much higher concentrations than T3. The model only incorporates TPO inhibition, it is assumed that iodine concentrations are not changing and the contribution of the blocking effects of PTU on gland deiodinase activity is minimal. PTU-induced TPO inhibition is described as function of I max ( maximal percent inhibitory response from PTU exposure), IC 50 (concentration of PTU that reduces TPO activity by half), and concentrations of T4 and PTU in the thyroid gland (Table 1 ). An I max of 0.94 and IC 50 of 1.28 mM were taken from an in vitro rat microsomal-based assay reported by Paul et al. (2014) . In vitro IC 50 was applied to in vivo conditions by dividing 1.28 mM by 0.24, the unbound fraction of PTU from Kampmann and Molholm Hansen (1983) . To maintain homeostatic steady state levels of T4 in absence of chemical, the production rate of T4 (Ksyn) in the gland was estimated by multiplying baseline levels of T4 concentration in the absence of PTU with 1.38, the elimination rate of T4 in the gland (Kdeg) obtained from Silva et al. (1984) . The empirical relationship for predicting levels of T4 in thyroid tissue in response to TPO inhibition is described in equation 2:
TPO inhibition was determined by equation 3 and this simulation depicted in Figure 4A :
The relationship between gland PTU and gland T4 concentrations depicted in Figure 4A is maintained further downstream where gland T4 concentrations are closely aligned with serum T4 concentrations ( Figure 4B ). This relationship is described quantitatively by y ¼ 0. these 2 measures were highly correlated with each other ( Figure 5D , r 2 ¼ 0.98) and fit to the function y ¼ 0.5772
(equation 5). Levels of T3 and T4 in fetal serum were also substantially lower than levels in the dam. T4 was decreased by 35%, 60%, 83%, and 90% at 0.5, 1, 2, and 3 ppm, respectively, with no change at the lowest dose of 0.1 ppm ( Figure 5B , F[5,41] ¼ 15.28; p < .0001). Importantly, hormone reductions in fetal serum were apparent at doses that were not significantly altered in the dam (0.5 and 1 ppm). The slight increment in T4 observed at the lowest dose in dam serum was not evident in the fetal serum (compare Figs. 3B and 5B). In contrast to the dam, fetal serum T3 was reduced in a dose-dependent manner ( Figure 5C, F ( Figure 5E ; equation 6). This relationship reflects DF5 depicted in Figure 2 . Concentrations of T4 in the maternal and fetal serum (KER2 of Figure 2 ) were highly correlated (r 2 ¼ 0.95) and fit to the y ¼ 0.198e 0.139x ( Figure 5F ; equation 7). Despite lower concentrations of PTU in fetal serum, a steeper decline in serum T4 with increasing dose was evident in the fetus than in the dam.
Contributions from Dam and Fetus to Fetal Serum T4
T4 measured in the fetal serum (KE2 fetus of Figure 2 ) is a composite of placental transfer of T4 from the dam (KER2) and that synthesized and released from the newly functioning fetal thyroid gland (MIE fetus , KE1 fetus ). On GD20, approximately 17% of fetal serum T4 derives from the maternal source (Morreale de Escobar et al., 1990). We attempted to parse out these 2 sources of T4 to derive an estimate of TH derived from the fetal thyroid gland to inform the fetal MIE (MIE fetus ). The proportional contribution of T4 from maternal serum to that measured in the fetal serum on GD20 was estimated by equation 8 as follows:
T4 dam serum Â ratio of placenta :dam T4 Â placenta weight Â litter size Â TF T4 fetal serum Â litter size Â fetal body weight :
The ratio of T4 in placenta:dam serum was set to 0.28 based on data reported by Versloot (1998) ; placenta and fetal weights were set to 0.45 and 2.5 g, respectively (Rout and Dhossche, 2010) , mean litter size, dam and fetal serum T4 levels were derived from the current study. A placental to fetal transfer factor (TF) of 0.66 was applied to force the equation to yield 17% as per Morreale de Escobar et al. (1990) . This TF was assumed to remain constant across all doses of PTU. The calculated contribution from the dam was then removed from observed fetal serum T4 levels to yield the "fetal alone" T4 source. As shown in Table 2 , from these derivations, the relative proportion of T4 emanating from the dam and contributing to the fetal circulation at this stage of gestation appears to increase with increasing concentrations of PTU from 17% at 0 ppm to 34%À46% at the highest doses. Despite this increase, fetal T4 still falls precipitously with increasing dose of PTU suggesting a direct action of PTU to inhibit TPO in the fetal thyroid gland (MIE fetus , Figure 2 ).
Serum T4 Levels in the Fetus as a Function of Gestational Time and PTU Dose
Serum concentrations of TH change over the course of pregnancy in dam and the fetus (Morreale de Escobar et al., 2004; Ruiz de Ona et al., 1988) . Up until functional maturity of the fetal thyroid gland, the sole source of hormone to the developing fetus is provided by the maternal transport of T4 through the placenta (Morreale de Escobar et al., 2004) . During late gestation (GD17-18), fetal TH production increases and maternal serum concentrations of TH typically drop by about 50% of nonpregnant state (Fukuda et al., 1980; Hapon et al., 2003) . In order to improve our predictions, a more accurate representation of this dynamic phase of hormonal change was afforded by a second experiment in which serial blood samples were collected on GD10, GD15 and GD20 from pregnant dams exposed to 0 or 3 ppm PTU (Table 3) . Consistent with previous findings, circulating levels of T4 in dams declined from GD10 to GD20, and a parallel drop in serum T4 was evident in response 3 ppm of PTU ( Figure 6A , F[1,13] ¼ 7.76, p < .01). Dam serum T4 values were empirically fit to the exponential function (equation 9):
where y is the dam serum T4 concentration (ng/ml) and t is gestational time (days). Best fit modeling of the two 0 and 3 ppm PTU dose levels yielded estimates for the coefficients a (with 95% confidence bounds) as 192.5 (37.82, 347.2) , and b as À0.1954 (À0.2686, À0.1222), respectively. The ratio of T4 in the placenta: dam serum (0.28) (Versloot, 1998) was multiplied by placenta weight (0.45 g) (Rout and Dhossche, 2010) , mean litter size, dam serum T4 levels (observed), and 0.66, a placental to fetal transfer factor (TF) used to force the derived equation to yield 17%, the estimate of fetal serum T4 attributed to the maternal source . This percentage was assumed to remain constant across all doses of PTU. The values obtained from the dam were then divided by mean fetal weights (2.5 g) (Rout and Dhossche, 2010) , litter size (observed) and fetal serum T4 levels (observed) to calculate the dam contribution at each dose of PTU. The calculated contribution from the dam was then removed from the fetal T4 levels to yield the fetal alone T4 levels.
c Expressed as percent of control.
The generated time-course function of maternal serum T4 from Experiment 2 was then used to derive a more general empirical function, scaling the time-course function to predict T4 concentrations over the range of PTU dose levels directly assessed in Experiment 1 where measures were limited to GD20. This resulted in the following general equation describing T4 in dam serum as function of both gestational time and applied PTU dose as equation 10:
ð192:5 Â e À0:195t Þ Â e À0:138ð3ÀdÞ ;
where t is gestational time in days and d is dose of PTU in ppm. These estimates were then used to predict T4 levels in dam serum over gestational time at each dose of PTU as summarized in Figure 6B . In a similar manner, based on the strong correlation of dam and fetal serum T4, we then simulated fetal serum T4 concentrations over gestational time at all concentrations of PTU according to equation 11:
À5 Â e 0:54t Â e À0:009d ;
where y is T4 in fetal serum (ng/ml), t is gestational time in days and d is applied PTU dose in ppm. Simulation results based on this equation are summarized in Figure 7A .
Estimating Fetal Brain T4 Concentration Brain concentrations of TH were not assessed in this study. Rather, from the simulations of fetal serum T4 over gestational time, a relationship between fetal serum and brain T4 levels (KER3 of Figure 2 ) was established using information reported in Ruiz de Ona et al. (1988) . From the values reported in Figure 1 of Ruiz de Ona et al (1988) , a relationship of fetal serum T4 and fetal brain T4 was fit as a simple linear function y ¼ 0.37x À 0.056 (r 2 ¼ 0.96; equation 12) with a slope of 0.38 and is depicted in Figure 7B . The linearity of this relationship is indicative of a simple partitioning between these 2 matrices. Consequently, T4 levels in fetal brain for multiple doses of PTU during gestation were estimated by multiplying the fetal serum levels in Figure 7A by the slope of the line in Figure 7B (ie, equation 13 ¼ equation 11Â 0.38). The resulting simulations shown in Figure 7C depict T4 levels in the fetal brain during gestation, and describe KE3 and KER3 of Figure 2 .
Correlation of Serum and Fetal Brain T4 Levels With Heterotopia Volume
The final step in the quantitative analysis of the AOP (qAOP) was to define the relationship between fetal brain TH reductions and the presence/size of the cortical malformation, the heterotopia, in the brain of the offspring (the AO of Figure 2 ). Cells within the heterotopia are born in late gestation and once present, this malformation persists in the brain of the offspring throughout its life. It increases in size as a function of maternal dose of PTU and serum T4 declines, and prenatal exposure is essential to its formation (Gilbert et al., 2014; Goodman and Gilbert, 2007 ). An empirical equation was derived for the T4 levels in the fetal brain as a function of both gestational time and applied PTU dose. The AUC estimates for fetal brain T4 were incorporated to derive the mathematical relationship between fetal brain T4 and heterotopia volume reported previously by Gilbert et al. (2014) for doses of PTU of 1, 2, 3 and 10 ppm. This relationship is described by equation 14: Blood was sampled from the tail on GD 10 and GD 15 and trunk blood was collected at sacrifice on GD 20. **Significant difference from controls p < .05. Figure 6 . Dam serum T4 levels over gestational time. A, Results of serial sampling of serum T4 from 0 and 3 ppm PTU-treated dams reported in Table 3 of T4 levels (symbols) and simulations for 0 (dash line) and 3 ppm (dotted line). B, Simulations of dam serum T4 levels at multiple doses of PTU were established across multiple doses based on data collected at GD 20. Simulations from (A) are repeated, dam serum T4 data at GD 20 are shown as solid points and results of simulations are shown for 0, 0.1, 0.5, 1, 2, and 3 ppm.
where y is the volume of heterotopia in mm 3 , and x is the applied dose. Figure 8A . The large heterotopia induced at the highest dose of PTU of 10 ppm reported by Gilbert et al. (2014) , a dose that was not directly assessed in the current study, resulted in a skewed distribution evident in Figure 8A . The inset in Figure 8A depicts the lower doses of PTU (0, 1 and 2 ppm) from Gilbert et al. (2014) where the relationship appears more linear. A critical volume was nominally set to 0.003mm 3 based on the largest volume observed in any control animal, so by definition any volume in excess of this would be deemed abnormal or adverse. Gilbert et al. (2014) also depicted heterotopia volume using a volume index score, a categorical binning of volume on a scale of 0À4. Animals in which no evidence of cells within the heterotopia region were assigned a value of 0. On occasion, a small cluster of cells was present in 1 or several sections and this occurred in a percentage of control animals. Volume determinations in these animals did not exceed 0.003 mm 3 and were assigned a value of 1. Three subsequent volume ranges were defined that covered 2 orders of magnitude, animals whose heterotopia fell within these ranges assigned values of 2 (0.003À0.01 mm 3 ), 3 (0.01À0.10 mm 3 ), and 4 (>0.10 mm 3 ). The relationship of fetal brain T4 deficit using this metric of heterotopia volume is depicted in Figure 8B and is described by equation 15: ) occur with fetal serum T4 decrements of approximately 35% and at serum T4 Figure 7 . Fetal serum T4 levels over gestational time. A, Simulation of fetal serum T4 levels over gestational time 0 and 0.1 (dash line), 0.5, 1, 2 and 3 ppm based on AUC calculated for the dams in Figure 6 . The plot depicts experimental data for multiple PTU doses obtained at GD20 (black dots). B, Relationship between brain and serum T4 levels (KER3) derived from data presented in Figure 1 of Ruiz de Ona et al. (1988) . C, The relationship depicted in (B) permitted simulation of fetal brain T4 levels over gestational time at the multiple doses of PTU assessed in the present study.
decrements of approximately 20% in the dam. Although well described by linear fits, estimates derived by extrapolating to areas of the curve where no heterotopia volume data are available increases uncertainty in these predictions. All equations derived in the generation of this qAOP are summarized in Table 4 .
DISCUSSION
The main objective of this study was to develop an empirically derived qAOP to depict the impact of TH disruption on the developing brain in rats. Experiments were conducted to provide sufficient quantitative information for dose and time estimates of internal dose and serum TH in the pregnant dam and her progeny. These new data were coupled with existing information in the literature and fit to a series of empirical mathematical equations depicting the quantitative relationships between TPO inhibition, hormone synthesis impairments, serum and brain TH deficits, and a structural malformation in the brain of offspring in this rodent model. The strength of this manuscript lies in its report of direct observations in a gestational rodent model coupled with empirical modeling to move from a simple descriptive qualitative AOP to a more quantitative predictive description of this pathway.
The Maternal Compartment (DF1 DF2 DF3 MIE KE1 KE2 of Figure 2 ) It is well established that TPO inhibition leads to decreases in TH synthesis and PTU is a prototypic TPO inhibitor (Cooper et al., 1983) . In humans, rats, and amphibians, studies have shown that PTU is concentrated in the thyroid gland and affects intrathyroidal hormone metabolism (Lazarus et al., 1975; Marchant et al., 1972; Pharmakiotis and Alexander, 1975) . Our findings are consistent with these observations, and extend them to lower concentrations of PTU in a pregnancy model. Concentrations of PTU in the thyroid gland increased with increases in administered dose of PTU in the drinking water (DF1) and resultant PTU concentrations in serum (DF2). Iodination of thyroglobulin to form MIT and DIT and the coupling of these iodothyronines to form T3 and T4 are 2 processes catalyzed by TPO activity. All of these products within the thyroid gland were suppressed as a function of PTU administration with declines in thyroidal T4 being most sensitive (MIE dam ). PTU and T4 concentrations in the gland were used to develop a one-compartment model to estimate TPO inhibition, the MIE of this AOP. Decline in serum T4 concentrations in the dam (KE2 dam ) indicates that this TPO-induced decrease in T4 synthesis (MIE dam ) results in a decrement in T4 released (KE1 dam ) and measured in the circulation (KE2 dam ). The Fetal Compartment (DF4 MIE KE1 KE2) PTU readily crosses the placenta to reach the fetus (DF4) (Feng et al., 1996; Marchant et al., 1977) so presumably the same action on TPO described above for the dam thyroid gland is also taking place in the fetal thyroid gland. Our observations for maternal and fetal serum PTU concentrations are consistent with the 0.54 maternal: fetal ratios reported by Marchant et al. (1977) . The presence of PTU in the fetal serum when the fetal thyroid gland becomes functional (Fisher et al., 1976) indicates that the PTU-induced drops in fetal serum TH likely reflect both a more limited supply of TH from the dam (KE2) in addition to a direct action of PTU on the synthesis of TH in the fetal thyroid gland (MIE fetus ). The contribution of dam T4 to fetal serum T4 was described empirically to provide an estimate of fetal hormone production (MIE fetus ). Our model predicted that the "relative" proportion of T4 present in the fetal serum originating from the dam increases as the dose of PTU increases. From these estimates, the "fetal alone" contribution to "fetal total" serum T4 were made. The "fetal alone" contribution to total serum fetal T4 fell by 45% at a dose of PTU (0.5 ppm) that had no impact on circulating hormones in the dam. These data suggest that despite the dam as an additional source of T4 to the developing fetus, the fetal gland was still incapable of maintaining sufficient synthesis to avoid drops in serum T4 at doses of PTU that did not impact serum hormones in the dam. Importantly, these declines appear to be of sufficient magnitude to lower fetal brain TH concentrations that could initiate the formation of a brain heterotopia. Lower hormone and iodine reserves, a newly functioning yet still immature thyroid gland, and the high demands for TH of the growing fetus may all contribute to the greater relative drops in serum TH at lower doses in the fetus relative to the dam (Gilbert and Zoeller, 2010) .
From Serum to Brain to AO
The primary means whereby TH insufficiencies impart neurodevelopmental impairments is through T3-dependent gene (Zoeller et al., 2002) . As such, the fetal brain concentrations of TH are an essential component of the model predicting neurodevelopmental sequelae. Although T3 is the active hormone-mediating gene transcription events that modulate brain developmental programs, and presumably underlying the formation the heterotopia, we chose to model brain T4 for the following reasons. T4 is the primary hormone crossing from the maternal compartment to the fetus. T4 is the primary hormone taken up from the fetal circulation to the fetal brain Grijota-Martinez et al., 2011) . Finally, brain T3 is largely derived locally from brain T4 by activation of brain deiodinases, specifically Dio2 (Bernal, 2015; Calvo et al., 1990; Grijota-Martinez et al., 2011) . Simulations of dam and fetal serum from the current study were coupled with reported values of brain T4 to derive fetal brain hormone concentrations over gestational time. The results of these simulations coupled with previous reports from our laboratory permitted an estimation of the degree of T4 deficit in the fetal brain that would result in a structural brain defect (Gilbert et al., 2014) . Although both dam and fetal serum T4 are highly correlated with heterotopia volume, model predictions reveal these simple correlations under predict the severity of impact of serum hormone insufficiencies on brain T4 and subsequent formation of a structural defect in the brain of the offspring.
Additional Action of PTU on TH Economy
In the present model, the primary action of PTU to inhibit TPO was not dissociated from its known actions to inhibit deiodinase 1 (Dio1), an enzyme responsible for converting T4 to T3. Dio1 in the liver is generally assumed to produce most of the T3 found in circulation, but a contribution of thyroidal Dio1 to circulating T3 has been suggested in the rat, especially under conditions of severe hypothyroidism (Kohrle, 1999) . In Dio1 knock out models, however, very little effect is seen on circulating levels of T3 and T4, suggesting that Dio1 may serve a critical role in iodide conservation, but may not be essential for the maintenance of serum hormones (Galton et al., 2009) . PTU has no effect on Dio2, the deiodinase expressed in brain and responsible for conversion of T4 brain to T3 brain (Bernal, 2015; Guadano-Ferraz et al., 1999) . Based on these observations we submit that at the concentrations of PTU used in the present study, the contribution of Dio1 is minor relative to the primary action of this drug to inhibit TPO. Consistent with these findings, at the moderate doses of PTU used in this study, there was no impact on serum T3 concentrations measured in the dam. A PTU-induced block of Dio1 in the gland or in the periphery may have contributed to decrements we did observe in T3 in fetal serum. However, very low levels of Dio1 expression in fetal tissues (Bates et al., 1999) support our contention that TPO not Dio1 is the primary site of PTU action under the conditions of this study for both dam and fetus.
Limitations of the Approach
It is fully acknowledged that the simple modeling approaches of a complex biologic system that were implemented here do not account for all aspects of placental transport of chemical and hormone, feedback regulation in the dam and in the fetus, transport and local regulatory control of TH, and partitioning/ transport of TH from fetal serum to brain. Neither have we incorporated the complexities of TH metabolizing enzymes in the brain and specific transporters for TH and how they change over developmental time. Markers of TPO inhibition available in the dam thyroid were not possible in the fetal gland and the additional action of PTU to inhibit peripheral deiodination of T4 by its actions on Dio1 was not considered. Additional quantitative information on heterotopia at lower doses, incorporation of a temporal component into fetal hormone estimates, and the identification of underlying signaling pathways that lead to heterotopia formation may lead to improvements in model predictions. Finally, it is not known if heterotopia associated with TH insufficiency occur in humans and species differences in TH economy and differential timelines over which brain development exist between rodents and humans (Zoeller and Rovet, 2004) . However, despite these limitations, we present a quantitative description of several key elements in a thyroid AOP that has direct implications for interpretation and evaluation of the potential effects of thyroid disrupting chemicals on developing brain. Existing models have predicted hormone alterations in serum Lumen et al., 2013) , but have not provided a link to neurodevelopmental outcome. This empirically derived qAOP, admittedly limited to a model chemical of TPO inhibition, is an initial step to fill that gap.
Implementation and Utility
A number of distinct MIEs have been identified that can lead to altered TH signaling and as such hold the potential to impair brain development (Murk et al., 2013) . Despite quite disparate initiating events (several of which in the thyroid gland itself are depicted in Figure 1 ), many of these actions culminate further downstream as reductions in circulating TH, most notably, T4. Convergence of the action of a number of thyroid disrupting chemicals acting at distinct MIEs (at both intra-and extra-thyroidal sites) on a common downstream "integrator" KE such as serum hormone, lays the foundation for the development of AOP networks. AOP networks provide a more comprehensive depiction of biologic complexity of the thyroid system, the multiple points whereby chemicals and chemical mixtures may interface to disrupt it, and the downstream toxic events that follow from that chemical interaction (Villeneuve et al., 2014) .
The strong correlations between maternal and fetal serum T4 revealed here also provide quantitative support for the use of serum T4 as a metric for point of departure in regulatory analysis of thyroid disrupting chemicals. Reductions of 35% in fetal serum T4, and approximately 20% drops in dam serum T4 at GD20 were associated with volumes of heterotopia in excess of that seen in controls. Results of modeling clearly demonstrate the increased vulnerability of the fetus to hormone disruption from TPO inhibition and that fetal brain T4 deficits occur in the absence of any indication of hormone decrements in the dam. Furthermore, simulations using AUC estimates of brain T4 decrements suggest that even very modest reductions in fetal serum T4 may negatively impact fetal brain hormone concentrations and result in a brain malformation. Because PTU disrupts fetal TH homeostasis by its actions at both maternal and fetal sites, it may result in more severe effects than agents that either do not cross the placenta or that work at sites less disruptive of fetal hormone homeostasis. However, despite the necessity for TH reductions on GD20, it is also possible that serum hormone reductions that extend into the early postnatal period may be necessary for full expression of the heterotopia and affect its size. Consideration of the temporal profile of change in serum and brain TH for TPO inhibitors and for thyroid disruptors acting at distinct MIEs will provide needed data to test and refine model predictions.
Exposure assessment is a critical component in evaluating chemical risk in humans. When direct external exposure metrics are not available, internal body measurements are used to estimate dose using reverse dosimetry. In the context of the information represented in this qAOP, moving upstream, serum PTU and TH measurements can be used as an internal measure of a chemical effect to back calculate administered dose. Moving downstream from serum TH, this qAOP also provides a means to reconstruct the fetal brain T4 deficit from fetal serum T4 regardless of the means whereby the chemical lead to the serum TH reduction. This concept of reconstruction and back calculation can also be applied to estimate the dose associated with certain magnitude of brain insult when data for outcome but not exposure are available.
Availability of a qAOP for thyroid disruption may also be employed to inform the interpretation of screening data. Recently 1074 xenobiotics were screened for in vitro TPO inhibition potential; over 300 chemicals were identified as putative TPO inhibitors in vitro and additional indicators of potential assay interference were used to further experimentally refine this list (Paul Friedman et al., 2016; Paul et al., 2014) . Leonard et al. developed a computational in vitro-to-in vivo extrapolation method to bridge nominal in vitro concentrations to in vivo doses of chemicals (Leonard et al., 2016 ). The computational method was then linked to a mechanistic model of TH synthesis to predict serum TH levels in adult rat and human (Leonard et al., 2016) . We applied a similar approach in the present study to develop a one-compartment model to estimate TPO inhibition in the dam thyroid gland. The qAOP described herein can also be applied to extend the approach described by Leonard et al. (2016) to fetal serum TH, fetal brain TH, and the development of brain malformations.
In summary, in this report we have provided direct measures of the biologic effects of TPO inhibition in the pregnant dam and fetus in a manner amenable to dose-response modeling. We have used mathematical predictive modeling to characterize decreases in maternal/fetal serum and fetal brain TH linking these to a defined developmental neurotoxic event within an AOP framework. One of the strengths of this paper is the extensive dose-response and the implementation of sensitive measurement tools of internal metrics of exposure and effect within the same animals establishing a firm basis for quantitative analysis with direct applicability to other TPO inhibitors. Future work will determine the degree to which these quantitative relationships, including any uncertainty associated with the predictive model, can be applied to the evaluation of thyroid disrupting chemicals that reduce serum TH by targeting distinct MIEs.
